tiprankstipranks
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Price & Analysis

1,387 Followers

ARWR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$20.67 - $39.83
Previous Close$25.5
Volume3.48M
Average Volume (3M)1.00M
Market Cap
$3.17B
Enterprise Value$2.90B
Total Cash (Recent Filing)$395.41M
Total Debt (Recent Filing)$118.92M
Price to Earnings (P/E)
Beta1.54
Aug 05, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.24
Shares Outstanding124,200,230
10 Day Avg. Volume1,257,028
30 Day Avg. Volume1,003,965
Standard Deviation0.20
R-Squared0.06
Alpha0.00514
Financial Highlights & Ratios
Price to Book (P/B)6.23
Price to Sales (P/S)13.16
Price to Cash Flow (P/CF)-8.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue81.82
Enterprise Value/Gross Profit12.06
Enterprise Value/Ebitda-6.65
Forecast
Price Target Upside90.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say
Clinical Trial ResultsArrowhead has reported positive topline data for the PALISADE phase III trial of plozasiran in familial chylomicronemia syndrome.
Pipeline AdvancementArrowhead continues to advance its muscle-targeted pipeline, which though early-stage, may soon shine and unlock substantial value for shareholders.
Regulatory MilestonesThe company expects to file an NDA for plozasiran in FCS around year-end, with a potential launch in 2025.
Bears Say
Clinical DevelopmentRisks include clinical development risk, competitor risk, novel modality risk, commercialization risk, reimbursement risk, pricing risk, business development risk, capital market and dilution risk, and disruptions to clinical trials owing to the war in Eastern Europe.
Financial PerformanceARWR remains engaged with FDA and potential strategic financing partners to resolve balance sheet overhang, which also drove 11/30 sell-off (-25%) and PT lowering from $60 to $50.
Product DevelopmentEnded development of preclinical program ARO-SOD1 and partnered HZN-457 due to a lack of commercial viability.
---

Financials

Annual

Ownership Overview

9.12%23.36%48.44%19.07%
48.44% Other Institutional Investors
19.07% Public Companies and Individual Investors

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

ARWR FAQ

What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $20.67 and its highest was $39.83 in the past 12 months.
    What is Arrowhead Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
    Arrowhead Pharmaceuticals’s upcoming earnings report date is Aug 05, 2024 which is in 44 days.
      How were Arrowhead Pharmaceuticals’s earnings last quarter?
      Arrowhead Pharmaceuticals released its earnings results on May 09, 2024. The company reported -$1.02 earnings per share for the quarter, missing the consensus estimate of -$0.472 by -$0.548.
        Is Arrowhead Pharmaceuticals overvalued?
        According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Arrowhead Pharmaceuticals pay dividends?
          Arrowhead Pharmaceuticals does not currently pay dividends.
          What is Arrowhead Pharmaceuticals’s EPS estimate?
          Arrowhead Pharmaceuticals’s EPS estimate is -$0.53.
            How many shares outstanding does Arrowhead Pharmaceuticals have?
            Arrowhead Pharmaceuticals has 124,200,230 shares outstanding.
              What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
              Arrowhead Pharmaceuticals reported an EPS of -$1.02 in its last earnings report, missing expectations of -$0.472. Following the earnings report the stock price went down -10.68%.
                Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
                Among the largest hedge funds holding Arrowhead Pharmaceuticals’s share is Slate Path Capital LP. It holds Arrowhead Pharmaceuticals’s shares valued at 118M.
                  ---

                  Company Description

                  Arrowhead Pharmaceuticals

                  Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
                  ---

                  ARWR Earnings Call

                  Q2 2024
                  0:00 / 0:00
                  ---

                  ARWR Stock 12 Month Forecast

                  Average Price Target

                  $48.70
                  ▲(90.98% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","91":"$91","39.25":"$39.3","56.5":"$56.5","73.75":"$73.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$48.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,39.25,56.5,73.75,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.91,28.993846153846153,34.07769230769231,39.16153846153846,44.245384615384616,49.32923076923077,54.41307692307693,59.49692307692308,64.58076923076923,69.66461538461539,74.74846153846154,79.8323076923077,84.91615384615385,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.91,25.81692307692308,27.723846153846154,29.630769230769232,31.53769230769231,33.44461538461539,35.35153846153847,37.25846153846154,39.16538461538462,41.072307692307696,42.97923076923077,44.886153846153846,46.793076923076924,{"y":48.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.91,24.147692307692306,24.385384615384616,24.623076923076923,24.860769230769233,25.09846153846154,25.336153846153845,25.573846153846155,25.81153846153846,26.049230769230768,26.286923076923078,26.524615384615384,26.762307692307694,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":35.4,"date":1686873600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.32,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.65,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.96,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.19,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.15,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.17,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.6,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.96,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.08,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.78,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.44,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.91,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Ascendis Pharma
                  Arcturus Therapeutics
                  Arvinas Holding Company
                  Crispr Therapeutics AG

                  Best Analysts Covering ARWR

                  1 Year
                  Keay NakaeChardan Capital
                  1 Year Success Rate
                  20/36 ratings generated profit
                  56%
                  1 Year Average Return
                  +36.67%
                  reiterated a buy rating 20 days ago
                  Copying Keay Nakae's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +36.67% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis